Company
Supernus Pharmaceuticals
Supernus Pharmaceuticals has 23 drugs tracked on RxWires: 5 post-market, 1 approved, 9 in Phase 3, 1 in Phase 2/3, 4 in Phase 2, 3 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| ZULRESSO® | Post-Market | Postpartum Depression |
| SPN-812 (600mg, QD) | Post-Market | Healthy Lactating Women |
| Botulinum Toxin Type B | Post-Market | Cervical Dystonia |
| SPN-538 | Post-Market | Migraine Disorders |
| APOKYN | Post-Market | Parkinson's Disease |
| OXTELLAR XR | Approved | |
| MYOBLOC | Phase 3 | Sialorrhea |
| SPN-810 (18 mg) | Phase 3 | Attention Deficit Hyperactivity Disorder (ADHD) |
| SAGE-547 | Phase 3 | Super-Refractory Status Epilepticus |
| Placebo | Phase 3 | Epilepsies, Partial |
| Brexanolone | Phase 3 | Post Partum Depression |
| SAGE-718 | Phase 3 | Huntington's Disease |
| SAGE-547 90 μg/kg/h | Phase 3 | Postpartum Depression |
| MYOBLOC Low Dose | Phase 3 | Sialorrhea |
| SAGE-547 60 μg/kg/h | Phase 3 | Postpartum Depression |
| Phase 2; Low Dose MYOBLOC (10,000 Units) | Phase 2/3 | Spasticity |
| SPN-817 | Phase 2 | Focal Onset Seizures |
| IR-TPM (Topamax) | Phase 2 | Migraine |
| SPN-821 2400 mg | Phase 2 | Major Depressive Disorder (MDD) |
| Functional Magnetic Resonance Imaging (fMRI) | Phase 2 | Attention Deficit Hyperactivity Disorder (ADHD) |
| SAGE-904 | Phase 1 | Healthy Volunteer |
| [14C]-NV-5138 | Phase 1 | Healthy Volunteers |
| SPN-804O | Phase 1 | Epilepsies, Partial |
Latest
- supernus pharmaceuticals filed 8-K
- supernus pharmaceuticals filed 8-K
- supernus pharmaceuticals filed 8-K
- supernus pharmaceuticals filed 8-K
- supernus pharmaceuticals filed 8-K
Follow Supernus Pharmaceuticals on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.